Volume 28, No 6, Jun 2018

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 28 Issue 6, June 2018: 613-615

RESEARCH HIGHLIGHTS

Dimethyl fumarate: targeting glycolysis to treat MS

Stefano Angiari ¹ and Luke A. O’Neill ¹

¹ School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland Correspondence: Correspondence: Stefano Angiari (ANGIARIS@tcd.ie)

Dimethyl fumarate (DMF) is an immunomodulatory drug used in patients with multiple sclerosis (MS) and psoriasis. Kornberg and colleagues shed new light on DMF activity, demonstrating that it blocks immune cell activation through inhibition of glycolysis via post-transcriptional modification of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which confirms the pro-inflammatory role of glycolysis and points to potential new targets to treat inflammatory diseases such as MS.

https://doi.org/10.1038/s41422-018-0045-3

FULL TEXT | PDF

Browse 1196